Travapress, eye drops 0.04 mg/ml 2.5ml

Name: Travapress, eye drops 0.04 mg/ml 2.5ml
SKU: 301600
Availability: InStock

€19.93

EAN: 5944728002395 SKU: 301600 Categories: Eye Treatment, Glaucoma, Medicine

Elevated intraocular pressure, GlaucomaReducing elevated intraocular pressure in: open-angle glaucoma; elevated intraocular pressure.

Active ingredient

Travoprost

Interaction

No clinically significant interactions have been described.

Directions for use

Topically. 1 drop in the conjunctival sac of the eye (eye) once a day, in the evening. To reduce the risk of systemic side effects it is recommended after instillation of the drug to squeeze the nasolacrimal duct by pressing on its projection area at the inner corner of the eye. If a dose of the drug is missed the treatment is continued from the next dose.

Special Instructions

Travapress may cause a gradual change in eye color by increasing the number of melanosomes (pigment granules) in the melanocytes. This effect is predominantly seen in patients with mixed iris coloration such as blue-brown, gray-brown, green-brown, or yellow-brown. This effect has also been noted in patients with brown iris coloration. The brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris of the eye, with all or part of the iris becoming more intense brown. The long-term effects on melanocytes and the consequences are currently unknown. Changes in iris color occur slowly and may go undetected for months or years. Patients should be informed of the possibility of irreversible changes in eye color before starting treatment. If only one eye is treated, persistent heterochromia may develop. No further increase in brown iris pigmentation has been reported after the end of travoprost therapy. Darkening of the eyelid skin and/or periorbital area has been reported in 0.4% of patients due to the use of travoprost.

Travoprost can gradually change the lash structure of the eye on which it is used; during clinical trials, such changes were observed in approximately half of patients and included increases in lash length, thickness, pigmentation, and number of lashes. The mechanism of change in lash structure and the long-term effects of this action are currently unknown.

There is no experience with travoprost in inflammatory eye disease, neovascular glaucoma, closed angle glaucoma, narrow angle glaucoma, or congenital glaucoma, and only limited experience with eye disease caused by thyroid disorders, glaucoma in patients with pseudophakia, pigmentary or pseudoexfoliative glaucoma.

Persons with aphakia, pseudophakia, rupture of the posterior lens capsule, and risk factors for cystoid macular edema should use Travapress with caution.

Contact of hervoprost with the skin should be avoided because rabbit studies have shown transdermal absorption of hervoprost.

Perhaps caution should be exercised when prescribing Hervaprost in patients with risk factors for iritis/veitis.

Prostaglandins and their analogues are biologically active material that can be absorbed through the skin. Therefore, pregnant women and women who intend to become pregnant should be careful to prevent direct exposure to the contents of the vial. If a significant amount of the contents of the vial accidentally comes into contact with the skin, the affected area should be washed thoroughly immediately.

Patients should remove contact lenses prior to Injection of Travapress, 15 minutes after Injection, before inserting contact lenses again.

Impacts on ability to operate motor vehicles and machinery:
Temporary blurred vision or other visual disturbances after use of the drug may affect ability to drive or operate machinery. If blurred vision occurs after injection, the patient must wait until visual clarity is restored before driving motor vehicles or operating machinery.

Contraindications

Hypersensitivity to the drug components, children under 18 years of age, pregnancy and breast-feeding

Side effects

The overall profile of adverse reactions in clinical studies showed that conjunctival injection and iris hyperpigmentation were the most common adverse events, with an incidence of 20% and 6%, respectively.

The incidence of adverse reactions is given according to the following classification: Very common (>1/10), common (>1/100 to <1/10), infrequent (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000), very rare (<1/10,000), with unknown frequency. Within each group, adverse events are presented in decreasing order of severity. Adverse events are reported from clinical trials and post-registration follow-up.

System-organ class	Incidence
Infectious and parasitic diseases	Infrequent: Infectious eye lesion caused by Herpes simplex, herpetic keratitis.
Immune system disorders	Infrequent: hypersensitivity, hypersensitivity to drugs, seasonal allergies.
Nervous system disorders	Infrequent: loss of visual fields, dizziness, headache. Rarely: dysgeusia.
Mental disorders	With unknown frequency: depression, anxiety.
Visual organ disorders	Very common: conjunctival injection. Often: iris hyperpigmentation, pain in the eye, discomfort in the eye, “dry” eye syndrome, itching in the eye, eye irritation. Infrequent: Corneal erosion, uveitis, iritis, keratitis, pitting keratitis, photophobia, blepharitis, ocular discharge, eyelid erythema, periorbital edema, itching of eyelids, decreased visual acuity, blurred vision, lacrimation, conjunctivitis, ectropion, cataracts, crusts on the edges of eyelids, increased lash growth, discolored lashes, asthenopia, anterior chamber inflammation. Rarely: photopsia, eyelid eczema, conjunctival edema, iridescent circles around light sources, conjunctival folliculosis, eye hypoesthesia, meibomitis, pigment dispersion in the anterior chamber of the eye, mydriasis, thickened lashes, eye inflammation. With unknown frequency: macular edema, sunken eyeballs.
Hearing and labyrinth disorders	With unknown frequency: vertigo, tinnitus.
Heart disorders	Infrequent: sensation of palpitations. Rarely: irregular heartbeat, decreased heart rate. With unknown frequency: chest pain, bradycardia, tachycardia.
Vascular disorders	Rarely: decreased diastolic blood pressure, increased systolic blood pressure, hypotension, hypertension.
Respiratory, thoracic and mediastinal disorders	Infrequent: Dyspnea, asthma, nasal congestion, throat irritation. Rarely: impaired respiratory function, pain in the oropharynx, cough, dysphonia. With unknown frequency: aggravation of the course of bronchial asthma.
Gastrointestinal disorders	Rarely: constipation, dry mouth, gastric ulcer exacerbation, gastrointestinal tract disorders. With unknown frequency: diarrhea, abdominal pain, nausea.
Skin and subcutaneous fatty tissue disorders	Infrequent: Increased skin pigmentation in the periorbital area, skin discoloration, changes in the structure of downy hair, hypertrichosis. Rarely: allergic dermatitis, contact dermatitis, erythema, rash, discoloration of downy hair, madarosis. With unknown frequency: itching, abnormal growth of downy hair.
Musculoskeletal and connective tissue disorders	Rarely: musculoskeletal pain. With unknown frequency: arthralgia.
Renal and urinary system disorders	With unknown frequency: dysuria, urinary incontinence.
General disorders	Infrequent: malaise. Rare: asthenia.
Laboratory abnormalities	With unknown frequency: elevated PSA (prostate-specific antigen) levels

Overdose

Toxicity in overdose with topical administration is unlikely. Treatment in case of accidental ingestion is symptomatic and supportive.

In case of local overdose of the drug the eyes should be rinsed with warm water.

Pregnancy use

Pregnancy

Similarities

Travatan, Travoprost-Optic

Additional information

Weight	0.010 kg
Shelf life	3 years. After opening the bottle the drops should be used within 4 weeks. Do not use after the expiration date!
Conditions of storage	Store at a temperature not exceeding 25°C. Store out of the reach of children!
Manufacturer	C.O.Rompharm Company S.R.L., Romania
Medication form	eye drops
Brand	C.O.Rompharm Company S.R.L.